Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp
about
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsTriazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingRare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2.Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.Trends in antifungal susceptibility testing using CLSI reference and commercial methods.New generation azole antifungals in clinical investigation.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Antifungals to treat Candida albicans.Impact of new antifungal breakpoints on antifungal resistance in Candida speciesIn vitro studies of the activity of dithiocarbamate organoruthenium complexes against clinically relevant fungal pathogens.Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.The antifungal activity of human parotid secretion is species-specific.Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.Efficacy of triazoles in a murine disseminated infection by Candida krusei.Newer antifungal agents.Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies.In vitro activity of essential oils extracted from plants used as spices against fluconazole-resistant and fluconazole-susceptible Candida spp.Effect of Blume Essential Oil on spp. Involved in Oral Infections
P2860
Q26863344-AD9489B1-F6D5-4C1C-9886-2D96CD6B7319Q34430768-9B073BD9-8353-4717-908D-40236C681968Q34647337-7B116910-3B64-477F-8906-7B56D4A67BA6Q35912243-18B4C9FE-ADBD-4184-8780-09FE29443FD4Q36491819-2BBB3AFD-8B7E-4396-B9C3-F47653FD1117Q36809333-F4ACE253-5FD9-4B55-97BA-68962C2E6BE6Q36822025-E8DACC15-4B5E-4732-AF3E-B0623170001FQ37048679-53D9747B-CEA3-4F1E-9EB0-4E9A8B7EDF1FQ37374804-37E468C1-E847-4AEE-90B5-0F5FB9377D45Q37557695-EC18D080-964D-4D7B-BCEC-EC1ABBD9CCD4Q37579222-1B9E1CD0-6883-49B5-B1E1-473FAEA6C416Q37608276-51465437-A857-4741-9AD5-D2A0F53AD959Q37763928-D98FC97F-D610-4EF4-A457-21E5EBF22AF4Q38323404-DC8FC697-ACBD-45F1-BC8F-01560EEB7815Q38989873-15B5B536-6831-4097-8767-F32DC0EE42B6Q41787736-FDFB3831-05F2-4756-BA81-3E5BF375A832Q41810151-3BECD9DD-0733-483D-8219-D43791800590Q41908678-4BE86F28-FE52-4687-BB90-C312D4CD0C1EQ42071108-19771139-14BF-4AC8-8643-D2B02B909EBDQ42078949-10A4564C-D572-4BB7-B051-253A16804EDBQ42545839-0DECEF56-BC9C-4851-B78E-4C62CE1C84AAQ42577834-085824C1-564B-415A-8575-D9677ECD4853Q44855715-6348357D-19ED-44A9-803C-814B189F0744Q46172019-69F3BA75-FF37-487D-A694-AC166BE4ECD1Q46255280-8EC27B9D-E8ED-4E11-B91C-F93A57D36617Q58695534-883598BC-4084-4843-8F69-B5AC9CA6D14F
P2860
Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cross-resistance between fluco ...... inical isolates of Candida spp
@ast
Cross-resistance between fluco ...... inical isolates of Candida spp
@en
type
label
Cross-resistance between fluco ...... inical isolates of Candida spp
@ast
Cross-resistance between fluco ...... inical isolates of Candida spp
@en
prefLabel
Cross-resistance between fluco ...... inical isolates of Candida spp
@ast
Cross-resistance between fluco ...... inical isolates of Candida spp
@en
P2093
P2860
P1476
Cross-resistance between fluco ...... inical isolates of Candida spp
@en
P2093
P2860
P304
P356
10.1128/JCM.42.7.3137-3141.2004
P407
P577
2004-07-01T00:00:00Z